
How much do you know about Janus kinase (JAK) inhibitors for ulcerative colitis (UC)? Learn more in this engaging clinic. This activity is intended for gastroenterologists, primary care physicians, physician assistants, nurses, and nurse practitioners. The goal of this activity is for learners to be better able to discuss the risks and benefits of JAK inhibitors for patients with UC.
Learning Objectives:
Upon completion of this activity, participants will:
- Compare the risks and benefits associated with JAK inhibitors in different patient populations with UC
- Initiate JAK inhibitor therapy in appropriate patients with UCff
Faculty:
Aline Charabaty, MD, AGAF, FACG
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Clinical Director, IBD Center
Sibley Memorial Hospital
Johns Hopkins School of Medicine
Washington, DC
Steering Committee Chairs of Program:
Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Philip Mease MD, MACR
Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, Illinois
Editor:
Roderick Smith, MS
Senior Medical Education Director, Medscape, LLC
Compliance Reviewer:
Amanda Jett, PharmD, BCACPAssociate Director, Accreditation and Compliance, Medscape, LLC
Nurse Planner:
Leigh Schmidt, MSN, RN, CNE, CHCP
Associate Director, Accreditation and Compliance, Medscape, LLC
Supporter Statement
This program is supported by an independent educational grant from AbbVie.
Released: March 22, 2024
CME expiration date: March 22, 2025
Midwest
If you missed our Midwest workshop, join us in-person or virtually at one of our remaining locations.
University of Chicago
Gleacher Center
Feb. 24, 2024
Course directors:
Northeast
If you missed our Northeast workshop, join us in-person or virtually at one of our remaining locations.
University of Pennsylvania
Jordan Medical Education Center - Law Auditorium
Jan. 20, 2024
Course directors:
Accreditation Statements
CME expiration date: March 22, 2025
Developed through a collaboration between American Gastroenterological Association, Crohn’s & Colitis Foundation and Medscape.
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
For Physicians
- Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
For Nurses
- Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net
Disclosure of Financial Relationships
Course Faculty:
Aline Charabaty, MD, AGAF, FACG, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Biotech, Inc.; Lilly; Pfizer, Inc.; Takeda
Please note: Participation by Dr. Charabaty does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Planners of Program (Steering Committee):
Peter Lio, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Almirall; Alphyn Biologics; Amyris; Arcutis Biotechnology; ASLAN; Boston Skin Science; Bristol Myers Squibb Company; Burt's Bees; Castle Biosciences; Codex Labs; Dermavant Sciences, Inc.; Eli Lilly; Galderma Laboratories, L.P.; Janssen; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kimberly Clark; LEO Pharma, Inc.; Lipidor; L'Oreal; Merck; Micreos; Regeneron Pharmaceuticals, Inc./Sanofi Genzyme Corporation; Sibel Health; Skinfix; Sonica; Theraplex; UCB Pharma, Inc.; Unilever; Verrica; Yobee Care
Speaker or member of speakers bureau for: AbbVie Inc.; Arcutis Biotechnology; Eli Lilly; Galderma Laboratories, L.P.; Hyphens Pharma; Incyte Corporation; La Roche-Posay/L'Oreal; Pfizer; Pierre-Fabre Dermatologie; Regeneron Pharmaceuticals, Inc./Sanofi Genzyme Corporation; Verrica
Research funding from: AbbVie Inc.; AOBiome
Contracted researcher for: AbbVie Inc.; AOBiome
Royalties from: Theraplex
Stock options from: Codex Labs; Yobee Care
Philip Mease MD, MACR, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Acelyrin; Aclaris; Alumis; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eli Lilly; Inmagene; Janssen; MoonLake; Novartis; Pfizer; Takeda; UCB Pharma, Inc.; Ventyx
Speaker or member of speakers bureau for: AbbVie Inc.; Amgen Inc.; Eli Lilly; Inmagene; Janssen; Novartis; Pfizer; UCB Pharma, Inc.
Research funding from: AbbVie Inc.; Acelyrin; Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly; Janssen; Novartis; Pfizer; UCB Pharma, Inc.
David T. Rubin, MD, has the following relevant financial relationships:
Consultant or advisor for: Altrubio; Amgen Inc.; Avalo Therapeutics; Bristol Myers Squibb Company; Buhlmann Diagnostics Corp; Chronicles Health; ClostraBio; Connect BioPharma; Cytoki Pharma; Douglas Pharmaceuticals; EcoR1; Eli Lilly; Ferring Pharma; Image Analysis Group; Index Pharmaceuticals; Iterative Health; Janssen Pharmaceuticals; Odyssey Therapeutics; Pfizer; Prometheus Biosciences; Reistone Biopharma; Samsung Neurologica; Sangamo Therapeutics; Shanghai Pharma Biotherapeutics USA; Takeda; Tissium S.A.
Research funding from: Takeda
Stock options from: Altrubio; Iterative Health
Editor:
Roderick Smith, MS, has no relevant financial relationships.
Compliance Reviewer:
Amanda Jett, PharmD, BCACP, has no relevant financial relationships.
Nurse Planner:
Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.
Peer Reviewer:
This activity has been peer reviewed and the reviewer has no relevant financial relationships.